UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Cancer, 2018-12, Vol.124 (24), p.4618-4621

2018

Volltextzugriff (PDF)

Creating the High School Pipeline for Future Deaf Scientists in Academic Medicine

Academic medicine, 2023-11, Vol.98 (11), p.1235-1235

2023

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Insulin-like Growth Factor-l-Dependent Up-regulation of ZEB1 Drives Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2479-2488

2008

Volltextzugriff (PDF)

Abstract 590: Multiplex liquid biopsy for AR pathway activity in metastatic androgen receptor-positive triple negative breast cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.590-590

2021

Volltextzugriff (PDF)

Abstract PS5-35: Detection of PI3K pathway activation in circulating tumor cells in PIK3CA mutated metastatic breast cancer as a putative predictive biomarker for PI3K inhibitor therapies

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS5-35-PS5-35

2021

Volltextzugriff (PDF)

21‐Gene recurrence scores

Cancer, 2012-02, Vol.118 (3), p.788-796

2012

Volltextzugriff (PDF)

Abstract P5-07-07: Combination of IGF1R/FAK inhibition and PI3K/mTOR inhibition in triple-negative breast cancers

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-07-07

2015

Volltextzugriff (PDF)

Abstract 1955: Simultaneous longitudinal assessment of PIK3CA genomic mutations and PI3K pathway activity in circulating tumor cells in metastatic breast cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1955-1955

2022

Volltextzugriff (PDF)

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2703-2703

2012

Volltextzugriff (PDF)

Abstract 1467: Inhibition of Cdk4 radiosensitizes breast cancer cells by increasing PP2A levels, and decreasing Bad136 phosphorylation

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.1467-1467

2012

Volltextzugriff (PDF)

Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes

Cancer, 2010-06, Vol.116 (11), p.2549-2559

2010

Volltextzugriff (PDF)

Abstract LB-206: Breast cancer 21 -gene recurrence scores: Are there racial disparities in testing, scores, treatment, and outcome

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.LB-206-LB-206

2010

Volltextzugriff (PDF)

Tamoxifen to raloxifene and beyond

Seminars in oncology, 2001-06, Vol.28 (3), p.260-273, Article asonc0280260

2001

Volltextzugriff (PDF)

Abstract CT051: Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT051-CT051

2019

Volltextzugriff (PDF)

Tamoxifen to raloxifene and beyond: Breast cancer. I

Seminars in oncology, 2001, Vol.28 (3), p.260-273

2001

Volltextzugriff (PDF)

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1112-TPS1112

2022

Volltextzugriff (PDF)

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.1005-1005

2020

Volltextzugriff (PDF)

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14640-e14640

2019

Volltextzugriff (PDF)

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2548-2548

2018

Volltextzugriff (PDF)

Abstract 342: Silencing of IGF1R induces mesenchymal-to-epithelial transition and inhibits the metastatic properties of triple negative breast cancer cells

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.342-342

2012

Volltextzugriff (PDF)

TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3163-TPS3163

2022

Volltextzugriff (PDF)

Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-02-02-OT1-02-02

2022

Volltextzugriff (PDF)

Abstract P1-13-14: Increased androgen receptor expression as a mechanism of acquired anti-androgen resistance in androgen receptor-positive triple negative breast cancer

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P1-P1-13-14

2023

Volltextzugriff (PDF)

Abstract 1388: Multi-template analysis in metastatic breast cancer blood samples

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1388-1388

2016

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Treatment And Research

ThemaHumans

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Social media and clinical trials: The pros and cons gain context when the patient is at the center

Creating the High School Pipeline for Future Deaf Scientists in Academic Medicine

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Insulin-like Growth Factor-l-Dependent Up-regulation of ZEB1 Drives Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells

Abstract 590: Multiplex liquid biopsy for AR pathway activity in metastatic androgen receptor-positive triple negative breast cancer

Abstract PS5-35: Detection of PI3K pathway activation in circulating tumor cells in PIK3CA mutated metastatic breast cancer as a putative predictive biomarker for PI3K inhibitor therapies

21‐Gene recurrence scores

Abstract P5-07-07: Combination of IGF1R/FAK inhibition and PI3K/mTOR inhibition in triple-negative breast cancers

Abstract 1955: Simultaneous longitudinal assessment of PIK3CA genomic mutations and PI3K pathway activity in circulating tumor cells in metastatic breast cancer

Abstract 2703: Final results of a phase 2 trial using a novel, non-anthracycline neoadjuvant chemotherapy regimen in Her2-positive breast cancer

Abstract 1467: Inhibition of Cdk4 radiosensitizes breast cancer cells by increasing PP2A levels, and decreasing Bad136 phosphorylation

Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes

Abstract LB-206: Breast cancer 21 -gene recurrence scores: Are there racial disparities in testing, scores, treatment, and outcome

Tamoxifen to raloxifene and beyond

Abstract CT051: Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer

Tamoxifen to raloxifene and beyond: Breast cancer. I

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB)

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Abstract 342: Silencing of IGF1R induces mesenchymal-to-epithelial transition and inhibits the metastatic properties of triple negative breast cancer cells

TARGET National: A U.K.-wide liquid-based molecular profiling program to enhance recruitment to early-phase trials

Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens

Abstract P1-13-14: Increased androgen receptor expression as a mechanism of acquired anti-androgen resistance in androgen receptor-positive triple negative breast cancer

Abstract 1388: Multi-template analysis in metastatic breast cancer blood samples

Aktive Filter

Suchergebnisse filtern